Company intelligence / Profile preview

Arena Pharmaceuticals

San Diego, California, United States

Ownership: Private
Employees: ~350
Development stage: Other

Overview

Arena’s leading asset, etrasimod, a selective oral S1P receptor modulator, showed promising Phase 2 results in ulcerative colitis; results from the Phase 3 ELEVATE-UC trial were anticipated in 2022. The company’s other assets were in Phase 2/early Phase 3 with differentiated mechanisms for immuno-inflammatory and cardiovascular indications.

Therapeutic areas: CardiovascularGastroenterologyDermatologyRheumatology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Boehringer Ingelheim (GPCR research partnership)Eisai (prior marketing partner for Belviq/lorcaserin for obesity)

Beyond the preview

Go deeper on Arena Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arena Pharmaceuticals.

Explore the full profile